Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00934089 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT00934089 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 31 participants.
The verdict
NCT00934089, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
This study will characterize the effect of PF-04217329, alone and in combination with latanoprost, on circadian intraocular pressure and blood pressure in glaucoma patients. Blood samples will be collected to measure the amount of active metabolite of PF-04217329 in the plasma following dosing.
Interventions
- DRUG latanoprost
- DRUG PF-04217329
- DRUG latanoprost vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2010-01 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00934089
The ClinicalTrials.gov registry entry for NCT00934089 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which latanoprost is the first listed.
NCT00934089 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00934089 about?
NCT00934089 is a clinical study titled "A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329". This study will characterize the effect of PF-04217329, alone and in combination with latanoprost, on circadian intraocular pressure and blood pressure in glaucoma patients. Blood samples will be collected to measure the amount of active metabolite of PF-04217329 in the plasma following dosing.
What is the current status of trial NCT00934089?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2010-01. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00934089?
The interventions under investigation include: latanoprost (DRUG), PF-04217329 (DRUG), latanoprost vehicle (DRUG).
Who is sponsoring clinical trial NCT00934089?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.